Berotralstat

From Wikipedia, the free encyclopedia

Berotralstat
Berotralstat Structure.svg
Clinical data
Trade namesOrladeyo
Other namesBCX7353, BCX-7353
License data
Routes of
administration		By mouth
Drug classPlasma kallikrein inhibitor
ATC code
Legal status
Legal status
Identifiers
  • 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
CAS Number
  • 1809010-50-1
  • as HCl: 1809010-52-3
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC30H26F4N6O
Molar mass562.573 g·mol−1
3D model (JSmol)
  • NCC1=CC(=CC=C1)N1N=C(C=C1C(=O)NC1=CC(=CC=C1F)[C@H](NCC1CC1)C1=CC=CC(=C1)C#N)C(F)(F)F
  • InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
  • Key:UXNXMBYCBRBRFD-MUUNZHRXSA-N

Berotralstat, sold under the brand name Orladeyo, is a medication used to prevent attacks of hereditary angioedema (HAE) in people aged twelve years and older.[1][3][4][5][2]

The most common side effects include abdominal pain, vomiting, diarrhea, back pain, and heartburn.[2]

Berotralstat was approved for medical use in the United States in December 2020,[1][2][6] and in the European Union in April 2021.[3]

History[]

Berotralstat was approved based on evidence from one clinical trial (Trial 1 /NCT03485911) of 120 participants with hereditary angioedema.[2] The trial was conducted at 40 sites in the United States, the European Union, and Canada.[2] Trial investigators evaluated participants 12 years and older[7] with hereditary angioedema for eight weeks to determine the number of attacks for each participant.[2] The trial enrolled only participants who had at least two attacks during the eight-week period.[2] Participants were assigned to receive one of two doses of berotralstat or placebo once every day for 24 weeks.[2] Neither the participants nor the investigators knew which treatment was being given until after the trial was completed.[2] All participants could use other medications for treatment of attacks.[2]

References[]

  1. ^ a b c "Orladeyo- berotralstat hydrochloride capsule". DailyMed. Retrieved 25 December 2020.
  2. ^ a b c d e f g h i j k "Drug Trials Snapshot: Orladeyo". U.S. Food and Drug Administration. 3 December 2020. Retrieved 25 December 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ a b c "Orladeyo EPAR". European Medicines Agency (EMA). 24 February 2021. Retrieved 12 July 2021.
  4. ^ Hwang JR, Hwang G, Johri A, Craig T (December 2019). "Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema". Immunotherapy. 11 (17): 1439–1444. doi:10.2217/imt-2019-0128. PMID 31635497.
  5. ^ Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, et al. (October 2020). "Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial". The Journal of Allergy and Clinical Immunology. 148 (1): 164–172.e9. doi:10.1016/j.jaci.2020.10.015. PMID 33098856.
  6. ^ "Orladeyo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 December 2020.
  7. ^ "Berotralstat (Oral Route) Side Effects - Mayo Clinic". www.mayoclinic.org. Retrieved 3 March 2021.

External links[]

  • "Berotralstat". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03485911 for "Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE (APeX-2)" at ClinicalTrials.gov


Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""